- Home
- A-Z Publications
- Current Pharmaceutical Design
- Previous Issues
- Volume 10, Issue 29, 2004
Current Pharmaceutical Design - Volume 10, Issue 29, 2004
Volume 10, Issue 29, 2004
-
-
Preface [Hot Topic: Treatment of Hypertension, Its Pathophysiology and the Clinical Use of Antihypertensive Drugs (Executive Editor: Gregory Y.H. Lip)]
More LessThis issue of Current Pharmaceutical Design, for which I have the honour to be Executive Guest Editor, addresses topical issues relating to the treatment of hypertension, its pathophysiology and the clinical use of antihypertensive drugs. Davis et al. [1] discusses antihypertensive drug development and the importance of ethnicity. They apply valuable lessons learnt from heart failure management and discuss the implic Read More
-
-
-
Drug Development and the Importance of Ethnicity: Lessons from Heart Failure Management and Implications for Hypertension
Authors: Michael D. Sosin, Gurbir S. Bhatia, Gregory Y.H. Lip and Russell C. DavisHeart failure is a common condition, associated with both poor prognosis and poor quality of life. In contrast to all other cardiovascular diseases, the prevalence of heart failure is increasing in the western world, and is likely to continue to do so as the population ages. In the UK, a significant proportion of patients with heart failure come from South Asian and African Caribbean ethnic groups. A large body of evidence exists th Read More
-
-
-
Sympathetic and Baroreflex Function in Hypertension: Implications for Current and New Drugs
By Guido GrassiThe sympathetic nervous system has moved towards center stage in cardiovascular medicine. The importance of the sympathetic activation in heart failure and in renal insufficiency progression and mortality is indeed now well established. In essential hypertension evidence has been provided that this may be the case, because sympathetic overactivity is a key factor in the pathophysiology of the disease, thereby pro Read More
-
-
-
Endothelial Dysfunction: Methods of Assessment and Application to Hypertension
Authors: Sunil Nadar, Andrew D. Blann and Gregory Y.H. LipInterest in the endothelium has been growing in recent decades and the traditional belief that it provides an inert interface between blood and the vessel wall is no longer the case. It is now clear that the endothelium produces a large number of substances that influence blood flow, and it is in turn affected by changes in the blood and the pressure of blood flow. Nitric oxide and endothelins are the major regulators of the vascul Read More
-
-
-
Antihypertensive Therapy and Endothelial Function
Authors: Sunil Nadar, Andrew D. Blann and Gregory Y.H. LipThe benefits of treating hypertension in terms of reduction of morbidity and mortality are well established. However, it is debatable whether this benefit is derived entirely from the effects of a reduced blood pressure or whether these agents exert effects over and above blood pressure reduction on the endothelium. Hypertension is associated with adverse changes (whether damage or dysfunction) in the endothelium. In Read More
-
-
-
Hypertension in Peripheral Arterial Disease
Authors: Denis L. Clement, Marc L. De Buyzere and Daniel A. DuprezPeripheral arterial disease (PAD) of the lower limbs is associated with a high cardiovascular morbidity and mortality. Intermittent claudication is the most common symptomatic manifestation of PAD, but is in its own value an important predictor of cardiovascular death, increasing it by three-fold, and increasing all-cause mortality by two-to-five fold. Hypertension is a risk factor for vascular disorders, including PAD. Of hypertensive Read More
-
-
-
Pathophysiology and Treatment of Obesity Hypertension
Authors: Marion R. Wofford and John E. HallExcess weight gain accounts for as much as 65-75% of the risk for essential hypertension and also greatly increases the risk for end stage renal disease (ESRD). Obesity raises blood pressure by increasing renal tubular reabsorption, impairing pressure natriuresis, and causing volume expansion due to activation of the sympathetic nervous system (SNS) and renin-angiotensin aldosterone system (RAAS), and by physical Read More
-
-
-
Propofol: Therapeutic Indications and Side-Effects
More LessPropofol (2, 6-diisopropylphenol) is a potent intravenous hypnotic agent which is widely used for the induction and maintenance of anesthesia and for sedation in the intensive care unit. Propofol is an oil at room temperature and insoluble in aqueous solution. Present formulations consists of 1% or 2% (w / v) propofol, 10% soyabean oil, 2.25% glycerol, and 1.2% egg phosphatide. Disodium edetate (EDTA) or metabisulfite is added Read More
-
-
-
Structurally Modified Analogues of Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP) As Future Antidiabetic Agents
Authors: Brian D. Green, Victor A. Gault, Finbarr P.M. O'Harte and Peter R. FlattGlucagon-like peptide-1(7-36)amide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are gastrointestinal insulin-releasing hormones involved in the regulation of postprandial nutrient homeostasis. These two incretin hormones are glucose-dependent stimulators of pancreatic beta-cell function, exhibiting a spectrum of secondary extrapancreatic activities, which favour the efficient control of blood glucose hom Read More
-
-
-
In Utero Gene Therapy: Prospect and Future
Authors: D. P. Chauhan, A. S. Srivastava, M. E. Moustafa, S. Shenouda and E. CarrierMany genetic disorders are reported to cause irreversible damage to the fetus before birth. In utero gene therapy may be an effective tool for correction of genetic disorders by replacing defective gene with normal one. There are many reasons for moving forward with in utero gene therapy. The most important reason is to provide early intervention as to prevent or slow dysfunction and morbidity. This approach may Read More
-
-
-
TNF-Related Apoptosis-Inducing Ligand (TRAIL): A Potential Candidate for Combined Treatment of Hematological Malignancies
Authors: Paola Secchiero, Mauro Vaccarezza, Arianna Gonelli and Giorgio ZauliTNF-related apoptosis-inducing ligand (TRAIL) is a member of the TNF gene superfamily, which induces apoptosis through engagement of death receptors. TRAIL is unusual as compared to the other cytokines of this family, as it interacts with a complex system of receptors consisting of two pro-apoptotic death receptors (TRAIL-R1 and TRAILR2) and three decoy receptors (TRAIL-R3, TRAIL-R4 and osteoprotegerin). Moreover, Read More
-
-
-
Point of NO Return for Nitrergic Nerves in Diabetes: A New Insight into Diabetic Complications
By S. CellekAberrations in nitrergic neurotransmission, due to a decrease in neuronal nitric oxide (NO) synthase (nNOS) protein, play an important role in the pathogenesis of autonomic neuropathy in diabetes. Until recently the mechanism of the decrease in nNOS protein content in nitrergic nerves during diabetes was debated. Two different views were prevailing, one attributing the nNOS decrease to nitrergic nerve degeneration, th Read More
-
Volumes & issues
-
Volume 31 (2025)
-
Volume 30 (2024)
-
Volume 29 (2023)
-
Volume 28 (2022)
-
Volume 27 (2021)
-
Volume 26 (2020)
-
Volume 25 (2019)
-
Volume 24 (2018)
-
Volume 23 (2017)
-
Volume 22 (2016)
-
Volume 21 (2015)
-
Volume 20 (2014)
-
Volume 19 (2013)
-
Volume 18 (2012)
-
Volume 17 (2011)
-
Volume 16 (2010)
-
Volume 15 (2009)
-
Volume 14 (2008)
-
Volume 13 (2007)
-
Volume 12 (2006)
-
Volume 11 (2005)
-
Volume 10 (2004)
-
Volume 9 (2003)
-
Volume 8 (2002)
-
Volume 7 (2001)
-
Volume 6 (2000)
Most Read This Month
Article
content/journals/cpd
Journal
10
5
false
en
